logo

Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe

Gen­eral

Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 Octo­ber 2017


    • Early bird registration

until 8th Sep­tem­ber 2017

1200 PLN + 23% VAT

or €340 + 23% VAT

    • Stan­dard registration

from 9th Sep­tem­ber 2017

2000 PLN + 23% VAT

or €570 + 23% VAT

    • Accom­pa­ny­ing persons

If you would like to bring a friend do please con­tact us.

If there is suf­fi­cient inter­est we will develop an

agenda for accom­pa­ny­ing persons.

There will be a mod­est fee.


    • Extra din­ner guest

270zl + 23% VAT

77 + 23% VAT


By reg­is­ter­ing you acknowl­edge that you have read the dis­claimer and under­stood the can­cel­la­tion policy


Pay­ment by bank trans­fer in Euros to: PKO Bank Pol­ski in Krakow

94 1440 1127 0000 0000 1386 1129

Pay­ment by bank trans­fer in Pol­ish zloty to: PKO Bank Pol­ski in Krakow

68 1440 1127 0000 0000 1134 2701

Kod BIC (Swift): BPKOPLPW

Reg­is­ter

Pow­ered by BreezingForms

Agenda

Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 October2017

This year’s theme:
“Invest­ment and com­mer­cial­iza­tion: time for inter­na­tion­al­iza­tion and collaboration”

Pre­lim­i­nary Agenda
Cor­rect on 22 May 2017

25 Octo­ber 2017
18.00 Reg­is­tra­tion open
18.00 Pre-​conference Drinks Recep­tion at the Hotel Stary
Spon­sored by Slater Heelis (UK)

26 Octo­ber 2017

MAIN CON­FER­ENCE STARTS

08.15 Reg­is­tra­tion Open
09.00

Wel­come

9.15 Ses­sion: The big pic­ture in life sciences

09.15

Talk: The inno­va­tion /​health­care mar­ket – Global view

TBC

09.45

Talk: Invest­ment in Inno­va­tion – should strat­egy be bipartisan

Mark Tre­herne, For­mer Gov­ern­ment Advi­sor (UK)

10.15

Talk: Doing health­care busi­ness in Poland

Michael Dem­bin­ski, British Pol­ish Cham­ber of Commerce

10.4511.30 Cof­fee &Networking
11.30 Ses­sion VC investment
11.30

Talk: Invest­ing in and run­ning high growth busi­nesses – per­sonal experiences

Joel Besse, Momen­tum Biotech, France

12.00

Talk: VC thoughts on the present

Kevin John­son, Medicxi (United King­dom)
Mar­iusz Borowiec or Tomasz Głowacki, Augere Ven­ture (Poland)
Kreske Nicle­sen, Max Planck Soci­ety (Ger­many)
Peter Dudek, Wellign­ton Part­ners (Germany)

12.4514.00 Net­work­ing lunch

14.00 Ses­sion: Tech Trans­fer

14.00

Talk: Tech Trans­fer — Deal Struc­tures and Legal Perspectives

Simon Wall­work, Slater Heelis (UK)

14.30

Talk: Tech Transfer

Gabor Lamm, EMBLEM Tech­nol­ogy Trans­fer GmbH (Germany)

15.00

Panel: Tech Trans­fer: Lessons to learn from mature mar­kets
Krzysztof Jakubczak, nanoEmi (Poland)
Gabriela Konopka-​Cupiał, CIT­TRU (Poland)
Joern Erselius, Max Planck (Ger­many)
Ste­fan Ogrodzin­ski, Bioc­ity (UK)

15.45

TEA & Networking

16.30

Arm Chair Dis­cus­sion: Deals in the CRO world
Jane Eis­ner, Quin­tiles (UK)

17.00

Talk: Start­ing, financ­ing and deals
Ian Nicol­son, Advent (UK)

17.30 Con­fer­ence close for the day
19.30

Net­work­ing drinks, Con­fer­ence Din­ner, Live Music: Restau­rant Pod Roza

27 Octo­ber 2017

07.45 Busi­ness Break­fast: Intel­lec­tual Prop­erty Man­age­ment
Spon­sored by WTS Patent (Poland)
Case Study: Rafal Witek, WTS (Poland)

09.00 Ses­sion: Com­pany Presentations

09.00

9 ten minute emerg­ing com­pany pitches.

10.30

Cof­fee & Networking

11.15

Ses­sion: The Pol­ish Early Stage Pharma Scene

11.15 Talk: Mag­dalena Marciniak, Selvita (Poland)
11.45

Talk: Marcin Szu­mowski, Oncoarendi (Poland)

12.15

Talk: Piotr Zien, Pol­pharma Bio­log­ics (Poland)

12.45

Panel: Busi­ness Devel­op­ment, Deals and Inter­na­tion­al­iza­tion
Andrew Mul­vaney, Sum­mit PLC (UK)
Mag­dalena Nalazek-​Migoń, LSI Fund, (Poland)

Oth­ers TBC

13.30

Con­fer­ence Close and summing-​up
Roland Kozlowski

Speak­ers

        • Nicolas-Beuzen
          Nico­las Beuzen
        • Mariusz-Borowiec
          Mar­iusz Borowiec
        • Michael-Dembinski
          Michael Dem­bin­ski
        • Peter-Dudek
          Peter Dudek
        • JaneEisner
          Jane Eis­ner
        • Jorn-Erselius
          Jorn Erselius
        • Tomasz-Glowacki
          Tomasz Głowacki
        • Krzysztof-Jakubczak
          Krzysztof Jakubczak
        • Kevin-Johnson
          Kevin John­son
        • Gabriela-Konopacka-Ciupal
          Gabriela Konopka-​Cupiał
        • Roland-Kozlowski
          Roland Kozłowskim
        • dr-Gabor-Lamm
          Gabor Lamm
        • Magdalena-Nalazek-Migon
          Mag­dalena Nalazek-​Migoń
        • Ian-Nicholson
          Ian Nichol­son
        • Stefan-Ogrodzinski
          Ste­fan Ogrodzinski
        • Marcin-Szumowski
          Marcin Szu­mowski
        • Mark-Treherne
          Mark Tre­herne
        • Simon-Wallwork
          Simon Wall­work

Nicolas-Beuzen

Nico­las Beuzen

Busi­ness Devel­op­ment Direc­tor. Nico­las has over 15 years’ expe­ri­ence work­ing for var­i­ous bio­phar­ma­ceu­ti­cal com­pa­nies in France, India and Poland, from large and mid-​size pharma, to start-​ups. In his dif­fer­ent roles includ­ing chief sci­en­tific offi­cer and busi­ness devel­op­ment direc­tor, he has gained broad and applied knowl­edge in the devel­op­ment of new chem­i­cal enti­ties (NCEs) and bio­log­ics for neu­rode­gen­er­a­tive dis­eases, oncol­ogy and rare dis­eases. Work­ing with high per­for­mance, inter­na­tional R&D teams, he obtained expe­ri­ence in eval­u­a­tion, nego­ti­a­tion and man­age­ment of strate­gic alliances and part­ner­ships. Nico­las is co-​inventor on 2 patents. He holds a PhD in mol­e­c­u­lar biol­ogy and genomics from the Uni­ver­sity of Glas­gow and a mas­ter in man­age­ment and admin­is­tra­tion from the Uni­ver­sité Lyon III in France.


Mariusz-Borowiec

Mar­iusz Borowiec

Marusz has been involved with the Ven­ture Cap­i­tal mar­ket since 2005; estab­lish­ment and man­age­ment of two VC funds (Bloober Team, Eva­tronix, OK sys­tem, Encja​.com, M & M Air­craft, Legimi, Vision Light, BioVen­tures Insti­tute), a mem­ber of the five seed funds invest­ment com­mit­tees estab­lished jointly with the largest research insti­tu­tions in Poland (about 80 invest­ments), co-​investor, entre­pre­neur. For 3 years he was the pres­i­dent of TFI BDM, pre­vi­ously a board member/​chief finan­cial offi­cer in the Mega­chemie /​Isso­glas /​Neoxe group. He started his pro­fes­sional career in 1996 as a secu­ri­ties bro­ker. Grad­u­ate from Cra­cow Uni­ver­sity of Tech­nol­ogy. He expanded his knowl­edge in post­grad­u­ate stud­ies in busi­ness man­age­ment at the Higher Admin­is­tra­tive and Man­age­ment School.


Michael-Dembinski

Michael Dem­bin­ski

Michael Dem­bin­ski was born in Lon­don in 1957. Edu­cated at War­wick Uni­ver­sity and The City Uni­ver­sity, he worked for 16 years at the Con­fed­er­a­tion of British Indus­try, nine years as man­ag­ing edi­tor of its monthly mag­a­zine, CBI News. In 1997, Michael moved to Poland with his young fam­ily to take up the posi­tion of direc­tor of com­mu­ni­ca­tions at Pol­ska Telewizja Kablowa (now UPC Pol­ska). In 1999, Michael became man­ag­ing direc­tor of clas­si­fied adver­tis­ing pub­lisher Trader​.com Pol­ska (now a part of Agora S.A.). Since 2002, he has been work­ing with the British Pol­ish Cham­ber of Com­merce, where he is chief advisor.‎


Peter-Dudek

Peter Dudek

Peter joined Welling­ton Part­ners in Feb­ru­ary 2016 as a Prin­ci­pal. Prior to join­ing Welling­ton, Peter was an Invest­ment Asso­ciate at Entre­pre­neurs Fund, a London-​based pan-​European ven­ture fund with more than $200m of assets under man­age­ment. Peter served as a Board Observer on Vasopharm and Opti­nose, and sup­ported mul­ti­ple trans­ac­tions across the life sci­ences port­fo­lio includ­ing invest­ments in Vasopharm, Opti­nose, Cytoo, Sequana Med­ical and Prosonix, as well as Prosonix’s sale to Circassia.

Before EF, Peter con­sulted for a num­ber of Euro­pean venture-​backed biotech­nol­ogy star­tups and was an interned Ana­lyst at Novar­tis Ven­ture Funds. In his prior life as a sci­en­tist, Peter worked in the field of ncR­NAs and chro­matin remod­el­ling as a Research Fel­low at the Uni­ver­sity of Oxford (Queen’s), obtained his PhD from the Uni­ver­sity of Geneva in oncol­ogy, and a BSc (Hons) in immunol­ogy from the Uni­ver­sity of British Colum­bia. He also con­ducted research on the Hepati­tis C virus at the BC Cen­tre for Dis­ease Control.


Jane-Eisner

Jane Eis­ner

Jane Eis­ner heads Euro­pean Sales and Account Man­age­ment for Quin­tiles­IMS, where she is respon­si­ble for the growth and deliv­ery of the R&D busi­ness port­fo­lio in Europe, includ­ing global strate­gic partnerships.

With more than 20 years with Quin­tiles, Jane has held a vari­ety of lead­er­ship posi­tions across sales, account man­age­ment and study deliv­ery. Build­ing on her strong per­for­mance track record, her pas­sion for cus­tomer ser­vice is a key attribute as she devel­ops part­ner­ing solu­tions for her cus­tomers. One of Jane’s proud­est achieve­ments cre­at­ing Quin­tiles’ “Global Access to Patients” group, which deliv­ers patient out­reach and engage­ment pro­grams plus an inves­ti­ga­tor part­ner pro­gram that is now core to R&D Solu­tions study delivery.

Jane holds a Bach­e­lor of Sci­ence degree in phar­macy from the Uni­ver­sity of Bath UK.


Dr-Jörn-Erselius

Jörn Erselius

Jörn Erselius is Man­ag­ing Direc­tor of Max Planck Inno­va­tion (MI), the tech­nol­ogy trans­fer agency of the Max Planck Soci­ety (MPG), the largest Ger­man basic research orga­ni­za­tion. He joined MI in 1991 as Patent– and Licens­ing Man­ager and was respon­si­ble for advis­ing inven­tors and com­mer­cial­iz­ing tech­nol­ogy in the life sci­ence field. Later he took over respon­si­bil­ity for the patent and licens­ing depart­ment of MI. He nego­ti­ated numer­ous license agree­ments and con­sulted many spin offs from Max Planck Insti­tutes, such as Evotec or Alnylam.

Jörn Erselius stud­ied Biol­ogy at the Uni­ver­sity of Hei­del­berg and joined for his PHD stud­ies the Depart­ment of Prof. Peter Gruss at the Max Planck Insti­tute for Bio­phys­i­cal Chem­istry in Göttingen.

In 2004 he received his “Mas­ter of Busi­ness Admin­is­tra­tion (MBA)”, main focus: Man­age­ment, from the Uni­ver­sity of Applied Sci­ences in Deggen­dorf. He wrote his mas­ter the­sis on the topic “Patent­ing biotech­no­log­i­cal inven­tions in Europe and the US”.

Since 2011 he is “Reg­is­tered Tech­nol­ogy Trans­fer Pro­fes­sional, RTTP” (granted by ATTP, the Alliance of Tech­nol­ogy Trans­fer Professionals).

Jörn Erselius served for four years as Vice Pres­i­dent of ASTP (Asso­ci­a­tion of Euro­pean Sci­ence & Tech­nol­ogy Trans­fer Pro­fes­sion­als) and rep­re­sents Max Planck Inno­va­tion and the Max Planck Soci­ety in boards of Max Planck spin offs and as expert in sev­eral national and inter­na­tional com­mit­tees (BMBF, BMWi, Euro­pean Com­mis­sion, OECD).


Tomasz-Glowacki

Tomasz Głowacki

Tomasz has been involved with Pri­vate Equity since 1999 when he joined the River­side Global Fund (now Senior Advi­sor CEE & Italy). Dur­ing his time at River­side he has par­tic­i­pated in more than 10 trans­ac­tions in and out of this IPO. He worked through­out Europe with a spe­cial focus on Ger­many and Italy. Oper­a­tional expe­ri­ence con­firmed by par­tic­i­pa­tion in man­age­ment boards of port­fo­lio com­pa­nies or their super­vi­sory boards include: Zetkama S.A, Arena Inter­na­tional Spa, Richter Chemie Tech­nik GmbH or Key­cast Oy. Pre­vi­ously, Interim Man­ager at The Recov­ery Group, where he was a mem­ber of the board of direc­tors, par­tic­i­pated in the restruc­tur­ing process. He began his pro­fes­sional career in 1993 with KPMG Bank­ing Ser­vices Sp. z o. o. Grad­u­ate from For­eign Trade of the War­saw School of Economics.


Krzysztof-Jakubczak

Krzysztof Jakubczak

Krzysztof Jakubczak, PhD, is a grad­u­ate from the Insti­tute of Opto­elec­tron­ics of the Mil­i­tary Uni­ver­sity of Tech­nol­ogy in War­saw (MSc) and Czech Tech­ni­cal Uni­ver­sity in Prague (PhD). Addi­tion­ally, has built his pro­fes­sional skills at Stan­ford Uni­ver­sity (USA), Lab­o­ra­toire d’Optique Appliquée – LOA (France), Korean Advanced Insti­tute of Sci­ence and Tech­nol­ogy – KAIST (South Korea), Desy Syn­chro­tron in Ham­burg (Ger­many), Uni­ver­si­dad de Sala­manca (Spain) and many others.

Krzysztof’s exper­tise cov­ers: med­ical devices, lasers, optics, infrared tech­nol­ogy, light detec­tion, sec­ondary sources, lith­o­g­ra­phy, vac­uum sys­tems, spec­tro­scopic meth­ods, and defense. Krzysztof is expe­ri­enced R&D engi­neer and man­ager in the opto­elec­tron­ics domain. He worked as a Deputy Project Man­ager at new R&D HiLASE Cen­ter in Czech Repub­lic on inno­v­a­tive laser tech­nolo­gies for indus­try. He was respon­si­ble there for busi­ness devel­op­ment and man­age­ment of a research pro­gram. Krzysztof’s com­mer­cial expe­ri­ence cov­ers run­ning engi­neer­ing depart­ment at a med-​tech com­pany, build­ing a com­pany from a startup phase to the fully oper­a­tion pro­duc­tion facil­ity, build­ing and man­ag­ing a num­ber of star­tups devel­op­ing var­i­ous new tech­nolo­gies (med-​tech, mate­r­ial sci­ences, opto­elec­tron­ics). He is also an active advi­sory con­sul­tant in com­mer­cial­iza­tion and tech-​transfer fields. He worked as an Oper­a­tions Direc­tor for the National Cen­ter for Research and Devel­op­ment where he with his team was respon­si­ble for eval­u­a­tion and com­mer­cial­iza­tion activ­i­ties in Life Sci­ences field (pharma, med-​tech, agro). Krzysztof coop­er­ates with Laser­Lab Europe, MIT Enter­prise Forum Poland, Pol­ish Stan­dard­iza­tion Com­mit­tee, investors and tech­no­log­i­cal innovators.


Kevin-Johnson

Kevin John­son

Prior to co-​founding medicxi, Kevin was a part­ner with Index Ven­tures for 12 years, hav­ing joined the firm’s life sci­ences team in 2003. Kevin spear­headed Index’s very first exper­i­men­tal asset-​centric invest­ment, in Pan­Genet­ics, which was later acquired by Abbott Phar­ma­ceu­ti­cals. He is cur­rently chair­man of Lev­i­cept Ltd., Apcin­tex and Crescendo Bio­log­ics as well as being a board mem­ber of sev­eral other star­tups. Prior to join­ing Index, Kevin was with Cam­bridge Anti­body Tech­nol­ogy (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Direc­tor and Chief Tech­nol­ogy Offi­cer. He led the devel­op­ment of CAT’s plat­form tech­nolo­gies and their appli­ca­tion in the dis­cov­ery of a num­ber of human anti­bod­ies, two of which are now on the mar­ket: Humira (Abbott Phar­ma­ceu­ti­cals) and Benlysta (Glax­o­SmithK­line). Kevin was part of the man­age­ment team that floated CAT on the Lon­don Stock Exchange; it was sub­se­quently acquired by AstraZeneca. Kevin received a BSc in Mol­e­c­u­lar Biol­ogy from Edin­burgh Uni­ver­sity and a PhD from Cam­bridge University.


Gabriela-Konopacka-Ciupal

Gabriela Konopka-​Cupiał

Gabriela Konopka-​Cupiał, PhD, Direc­tor of the Cen­tre for Tech­nol­ogy Trans­fer CIT­TRU at Jagiel­lon­ian Uni­ver­sity For 9 years she has been involved in tech­nol­ogy trans­fer at Jagiel­lon­ian Uni­ver­sity, for over 3 years as the per­son in charge of CIT­TRU. She shares respon­si­bil­ity for inno­va­tion and knowl­edge exchange pol­icy at JU, includ­ing the imple­men­ta­tion of national law related to com­mer­cial­iza­tion issues and the use of uni­ver­sity infra­struc­ture by exter­nal enti­ties. She is a co-​founder of the Pol­ish Net­work of Aca­d­e­mic Tech­nol­ogy Trans­fer Cen­tres (PACTT), of which she is a board mem­ber. She is a win­ner of the min­is­te­r­ial pro­gram ‘Inno­va­tion Bro­ker’. Since 2014 she has been a mem­ber of ASTP-​Proton – the Asso­ci­a­tion of Euro­pean Sci­ence and Tech­nol­ogy Trans­fer Pro­fes­sion­als (ASTP).


Roland Kozłowski

Roland Kozłowski

Kozlowski received a first class hon­ours degree from the Uni­ver­sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a ser­ial bioen­tre­pre­neur, investor and men­tor who has worked in the indus­try for over twenty five years. Roland was Chief Exec­u­tive Offi­cer of Lec­tus Ther­a­peu­tics and Sense Pro­teomic Lim­ited two ven­ture cap­i­tal backed com­pa­nies which he founded, built and sold. Dur­ing his career Roland has lead or played a key role in a many trans­ac­tions includ­ing com-​pany financ­ing, sale, pur­chase, financ­ing and in– and out-​licensing with a cumu­la­tive value of over $200m. Ear­lier in his career Roland ran Research Groups at the Uni­ver­sity of Oxford and Uni­ver­sity of Bris­tol where he pub­lished and patented in the life sci­ence field. He has been a Vis­it­ing Indus­trial Pro­fes­sor, served on, or advised the boards of sev­eral Euro­pean com­pa­nies and orga­ni­za­tions includ­ing the Bio-​Industry Asso­ci­a­tion in the UK. Presently he is pres­i­dent and owner of Life Sci­ence Biznes Con­sult­ing which spe­cial­izes in com­mer­cial­iz­ing tech­nol­ogy from emerg­ing economies par­tic­u­larly in Poland. He acts as advi­sor to the National Cen­tre of Research & Devel­op­ment in Poland and the Pol­ish Devel­op­ment Agency. He is a founder and lim­ited part­ner in Life Sci­ence Inno­va­tions a spe­cial­ist VC fund based in Poland, an advi­sor to Alder­ley Park Ven­tures (UK) and a num­ber of start-​up com­pa­nies who he also mentors.


dr Gabor Lamm

Gabor Lamm

Dr Jonathan Gee Invest­ment Direc­tor SPARK Ven­ture Man­age­ment Ltd and SPARK Impact Ltd

Dr. Lamm (born 1967 in Budapest) is a grad­u­ate of Edin­burgh Uni­ver­sity (Bio­chem­istry) and holds a Ph.D. in Mol­e­c­u­lar Biol­ogy. After spend­ing three years as a research sci­en­tist at the Boehringer Ingel­heim Insti­tute of Mol­e­c­u­lar Pathol­ogy (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global sup­plier of sil­i­cone and poly­mer raw mate­ri­als and semi­con­duc­tors. At Wacker Chemie Dr. Lamm was Business-​Team Leader in the divi­sion spe­cial­is­ing in advanced ceramic com­po­nents for high-​tech appli­ca­tions. As of Octo­ber 2000 he is Man­ag­ing Direc­tor of EMBL Enter­prise Man­age­ment Tech­nol­ogy Trans­fer GmbH (EMBLEM), a 100% sub­sidiary of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory (EMBL; http://​www​.embl​.org). Dr. Lamm is an alum­nus of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory Ph.D. pro­gram and of the Boehringer Ingel­heim Fonds, on the advi­sory board of var­i­ous asso­ci­a­tions and start-​up com­pa­nies, co-​founder of the VC vehi­cle EMBL-​Ventures, and for­mer vice-​president (20022006) of the Asso­ci­a­tion of Euro­pean Sci­ence and Tech­nol­ogy Trans­fer Pro­fes­sion­als (ASTP).


Magdalena-Nalazek-Migon

Mag­dalena Nalazek-​Migoń

Grad­u­ate from the Tech­ni­cal Uni­ver­sity of Lodz Depart­ment of Inter­na­tional Fac­ulty of Engi­neer­ing and the Fac­ulty of Orga­ni­za­tion and Man­age­ment. Expe­ri­enced and suc­cess­ful ser­ial entre­pre­neur and investor (founder, co-​owner and top exec­u­tive in 2 stat-​up com­pa­nies in busi­ness con­sult­ing and ser­vices sec­tor, worth cur­rently ~40M PLN). Last 7 years of pro­fes­sional expe­ri­ence in invest­ment funds as an Invest­ment Offi­cer, Investor and Board Mem­ber. Expe­ri­enced in invest­ment man­age­ment processes and sales process of inno­v­a­tive start-​up com­pa­nies. Pre­vi­ous expe­ri­ence in man­age­ment posi­tions in inter­na­tional orga­ni­za­tions in busi­ness ser­vices. Core com­pe­ten­cies: invest­ment man­age­ment processes and sales process of inno­v­a­tive start-​up com­pa­nies, set­ting up and man­age­ment of start-​up com­pa­nies, increase of com­pa­nies value, busi­ness devel­op­ment, build­ing effec­tive team.


IanNicholson

Ian Nichol­son

Ian has over 25 years of inter­na­tional expe­ri­ence in man­age­ment and trans­ac­tions within the life sci­ences sec­tor. In addi­tion to his role at F2G, he is cur­rently an Oper­at­ing Part­ner of London-​based Advent Life Sci­ences LLP. Ian pre­vi­ously spent eight years as CEO of the pri­vately held oncol­ogy R&D com­pany, Chroma Ther­a­peu­tics Lim­ited. Prior to that he was Senior Vice Pres­i­dent, Busi­ness Devel­op­ment at UK biotech­nol­ogy com­pany Cell­tech Group plc. Ian has worked exten­sively in licens­ing, M&A and mar­ket devel­op­ment in the UK, Europe and the US and holds a BSc (Hons.) from Uni­ver­sity Col­lege Lon­don and an MBA from Boston Uni­ver­sity. He holds Board posi­tions at Con­sort Med­ical plc, Clin­i­gen Group plc and Bioven­tix plc.


Stefan-Orgodzinski

Ste­fan Ogrodzinski

Ste­fan Ogrodzin­ski received his BSc (Hons) in Tox­i­col­ogy and Phar­ma­col­ogy from The School of Phar­macy, Uni­ver­sity Col­lege Lon­don, in 1987 and his MBA from De Mont­fort Uni­ver­sity in 1999. Stefan’s career has spanned the phar­ma­ceu­ti­cal indus­try, the health­care sec­tor, the vol­un­tary sec­tor and the edu­ca­tional sec­tor, giv­ing 25 years of sales, mar­ket­ing, man­age­ment and direc­tor­ship expe­ri­ence. In 2000, Ste­fan founded BioSta­tus and has led the com­pany as its CEO. As a found­ing Direc­tor of BioSta­tus, Ste­fan is respon­si­ble for the over­all direc­tion and strate­gic man­age­ment of the busi­ness. Ste­fan is also a Direc­tor of Bio­Sus­pen­sions, OncoTher­ics, BioC­ity, MediC­ity and Mobius. He sits on the advi­sory panel for the Cen­tre for Doc­toral Train­ing in Tar­geted Ther­a­peu­tics and For­mu­la­tion Sci­ence at Not­ting­ham Uni­ver­sity and serves as a UKTI Cat­a­lyst Ambassador.


Marcin-Szumowski

Marcin Szu­mowski

Marcin Szu­mowski is ser­ial entre­pre­neur. He received his MS and PhD degrees from the Uni­ver­sity of Illi­nois and earned an MBA degree in entre­pre­neur­ship and inter­na­tional finance. Fol­low­ing a suc­cess­ful research career in the United States, Marcin has been involved in tech­nol­ogy trans­fer and start-​up com­pa­nies since 2000 and has co-​founded and man­aged five start-​ups, includ­ing a med­ical diag­nos­tics com­pany Med­ical­go­rith­mics S.A. (www​.med​ical​go​rith​mics​.com), where he was Pres­i­dent and CEO 20052010. Med­ical­go­rith­mics is now traded on the War­saw Stock Exchange with a mar­ket cap over $300M and global sales. Since 2012 he is Pres­i­dent & CEO of OncoArendi Ther­a­peu­tics S.A. (www​.oncoarendi​.com), a Pol­ish inno­v­a­tive bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to devel­op­ing and com­mer­cial­iz­ing novel ther­a­peu­tics for neo­plas­tic and inflam­ma­tory dis­eases. In four years the com­pany has grown to almost 70 employ­ees and over $35M research fund­ing from pri­vate investors and pub­lic grants. Marcin is also one of co-​founders and lead investors in the Life Sci­ence Inno­va­tions (LSI) early stage fund. Since 2012 Marcin has also assisted the Euro­pean Com­mis­sion on three inde­pen­dent expert pan­els per­form­ing the impact assess­ment, interim and final eval­u­a­tions of the Inno­v­a­tive Med­i­cines Ini­tia­tive (IMI), the world’s largest public-​private part­ner­ship (PPP) in phar­ma­ceu­ti­cal research. Over the last 15 years Marcin has man­aged over 40 R&D and invest­ment projects with a total value well over $250M.


Mark-Treherne

Mark Tre­herne

Mark has been actively involved in the bio­phar­ma­ceu­ti­cal indus­try for 25 years and was a co-​founder in 1997 and Chief Exec­u­tive of Cam­bridge Drug Dis­cov­ery, lead­ing the Company’s acqui­si­tion by Bio­Fo­cus plc, where he then became a Com­mer­cial Direc­tor, dri­ving sig­nif­i­cant growth of its prof­itable ser­vices busi­ness. Mark has now served on the Boards of 15 pri­vate and pub­lic bio­phar­ma­ceu­ti­cal com­pa­nies in Aus­tralia, France, Den­mark, the Nether­lands and the UK. Mark joined the Life Sci­ences Organ­i­sa­tion (LSO) as Chief Exec­u­tive in 2012, fol­low­ing its for­ma­tion by‎ UK Trade & Invest­ment‎. While at the LSO he worked with the UK Gov­ern­ment to bring in £6 bil­lion in inward invest­ment, before leav­ing to return to the biotech­nol­ogy sec­tor in 2016. Mark is cur­rently Chief Exec­u­tive of Avilex Pharma in Copen­hagen. He ini­tially trained as a neu­ro­sci­en­tist and elec­tro­phys­i­ol­o­gist at Cam­bridge Uni­ver­sity in the 1980s.‎


Simon-Wallwork

Simon Wall­work

With over 28 years expe­ri­ence advis­ing on acqui­si­tions, dis­pos­als, pri­vate equity and pub­lic mar­ket trans­ac­tions, for a wide vari­ety of clients includ­ing pub­lic and pri­vate com­pa­nies, banks, ven­ture cap­i­tal funds and part­ner­ships, Simon also has con­sid­er­able client side expe­ri­ence spend­ing a num­ber of years work­ing in-​house with Pilk­ing­ton plc where he was involved in a num­ber of cross bor­der transactions.

Simon has worked in the life sci­ences sec­tor for over 20 years hav­ing acted on the list­ing of Oxford Mol­e­c­u­lar Group plc. He has acted for many com­pa­nies in the sec­tor from incor­po­ra­tion through fund­ing rounds to even­tual exit by way of sale or IPO. He has a deep under­stand­ing of the sec­tor and its key drivers.

Media

  • newsletter_luty_2017_a
  • newsletter_maj_s

Atten­dees

Under con­struc­tion

Dis­claimer

CAN­CEL­LA­TION POL­ICY & DISCLAIMER

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. allows a change of reg­is­trant at no extra cost if the orig­i­nal reg­is­trant is unable to attend.

In the event of can­cel­la­tion of the Con­fer­ence by the orga­niz­ers all fees paid by del­e­gates will be returned in full although Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not respon­si­ble for any other finan­cial losses such as travel and hotel costs.

In the event that a del­e­gate or accom­pa­ny­ing per­son can­cels atten­dance at the con­fer­ence Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. will return 60% of the reg­is­tra­tion fee if atten­dance is can­celled before Fri­day 18 Sep­tem­ber 2015. There­after there will be no return of fees.

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not liable in any way for any injuries, sick­ness or acci­dent or any costs incurred as a con­se­quence of such an event or any other losses to which a del­e­gate or accom­pa­ny­ing per­son may be sub­jected to whist trav­el­ling to or from Poland or whilst attend­ing the con­fer­ence in Krakow or any of the social events organized.

The speak­ers listed have all con­firmed their atten­dance and have agreed to post their pho­tographs on this web­site. How­ever Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. informs del­e­gates and speak­ers that that the final agenda could change for rea­sons beyond its con­trol. Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. reserves the right to make changes to the agenda and is not respon­si­ble for any finan­cial losses or costs incurred by par­tic­i­pants or del­e­gates in asso­ci­a­tion with their par­tic­i­pa­tion at this conference.

Spon­sors

spon­sors

selvitalogo selvitalogo wts

HON­ORARY PATRONAGE

NCBR

part­ners

malopolska centre of biotechnology logo Oncoarendi

media part­ner

biotechnologia dolina bio technologiczna pl logo
European Biotechnology Network

Hotels

Under con­struc­tion

Pre­sen­ta­tions

Under con­struc­tion